Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57099
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3397]
Metadata
Show full item record
IN VITRO INTERACTIONS OF MICAFUNGIN WITH OTHER ANTIFUNGAL DRUGS AGAINST CLINICAL ISOLATES OF FOUR SPECIES OF CRYPTOCOCCUS
Author
Affilliation
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Scientific Institute of Public Health. Brussels, Belgium.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Scientific Institute of Public Health. Brussels, Belgium.
Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut. Unitat de Microbiologia. Reus, Spain.
Abstract
The combination of micafungin (MFG) with amphotericin B (AMB), fluconazole, itraconazole, voriconazole, or ravuconazole was evaluated against 37 strains of four species of Cryptococcus by the checkerboard method. Antagonism was never seen. Synergy was observed for some isolates for each combination and was most frequent with MFG-AMB.
Share